Equities Analysts Offer Predictions for BioLineRx Ltd.’s Q1 2024 Earnings (NASDAQ:BLRX)

BioLineRx Ltd. (NASDAQ:BLRXFree Report) – Investment analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for shares of BioLineRx in a note issued to investors on Tuesday, March 26th. HC Wainwright analyst J. Pantginis expects that the biotechnology company will post earnings of ($0.29) per share for the quarter. HC Wainwright has a “Buy” rating and a $21.00 price target on the stock. The consensus estimate for BioLineRx’s current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for BioLineRx’s Q2 2024 earnings at ($0.29) EPS, Q3 2024 earnings at ($0.24) EPS and Q4 2024 earnings at ($0.22) EPS.

Separately, StockNews.com raised shares of BioLineRx to a “sell” rating in a research report on Wednesday.

Get Our Latest Stock Analysis on BioLineRx

BioLineRx Stock Up 0.9 %

BLRX stock opened at $1.12 on Thursday. The company’s 50 day moving average is $1.20 and its two-hundred day moving average is $1.46. BioLineRx has a twelve month low of $0.81 and a twelve month high of $2.53. The company has a current ratio of 1.96, a quick ratio of 1.86 and a debt-to-equity ratio of 0.64. The stock has a market cap of $81.13 million, a P/E ratio of -1.24 and a beta of 1.40.

BioLineRx (NASDAQ:BLRXGet Free Report) last issued its earnings results on Tuesday, March 26th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.07. The business had revenue of $4.80 million for the quarter, compared to analyst estimates of $0.17 million. During the same period last year, the business posted ($0.09) EPS.

Institutional Investors Weigh In On BioLineRx

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC raised its stake in BioLineRx by 278.0% during the 4th quarter. Renaissance Technologies LLC now owns 257,900 shares of the biotechnology company’s stock valued at $152,000 after acquiring an additional 189,678 shares during the last quarter. Atria Wealth Solutions Inc. acquired a new position in shares of BioLineRx in the first quarter valued at approximately $178,000. Envestnet Asset Management Inc. purchased a new stake in shares of BioLineRx during the first quarter worth approximately $88,000. LPL Financial LLC lifted its holdings in shares of BioLineRx by 152.7% during the fourth quarter. LPL Financial LLC now owns 117,710 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 71,134 shares during the period. Finally, PVG Asset Management Corp purchased a new position in BioLineRx during the 4th quarter worth $97,000. 1.56% of the stock is owned by hedge funds and other institutional investors.

BioLineRx Company Profile

(Get Free Report)

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.

Further Reading

Earnings History and Estimates for BioLineRx (NASDAQ:BLRX)

Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.